WH. In vivo selective expression of thyroid hormone receptor ␣1 in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice. Am J Physiol Regul Integr Comp Physiol 307: R340 -R346, 2014. First published May 21, 2014 doi:10.1152/ajpregu.00449.2013.-Ischemic heart disease (IHD) is the single most common cause of death. New approaches to enhance myocardial perfusion are needed to improve outcomes for patients with IHD. Thyroid hormones (TH) are known to increase blood flow; however, their usefulness for increasing perfusion in IHD is limited because TH accelerates heart rate, which can be detrimental. Therefore, selective activation of TH effects is desirable. We hypothesized that cell-type-specific TH receptor (TR) expression can increase TH action in the heart, while avoiding the negative consequences of TH treatment. We generated a binary transgenic (BTG) mouse that selectively expresses TR␣1 in endothelial cells in a tetracycline-inducible fashion. In BTG mice, endothelial TR␣ 1 protein expression was increased by twofold, which, in turn, increased coronary blood flow by 77%, coronary conductance by 60%, and coronary reserve by 47% compared with wild-type mice. Systemic blood pressure was decreased by 20% in BTG mice after TR␣1 expression. No effects on heart rate were observed. Endothelial TR␣1 expression activated AKT/endothelial nitric oxide synthase pathway and increased A2AR adenosine receptor. Furthermore, hearts from BTG mice overexpressing TR␣1 that were submitted to 20 min ischemia and 20 min reperfusion showed a 20% decline in left ventricular pressure (LVP) compared with control mice where LVP was decreased by 42%. Studies using an infarction mouse model demonstrated that endothelial overexpression of TR␣ 1 decreased infarct size by 45%. In conclusion, selective expression of TR␣1 in endothelial cells protects the heart against injury after an ischemic insult and does not result in adverse cardiac or systemic effects.
ISCHEMIC HEART DISEASE CONTINUES to be a significant medical problem. Therapeutic approaches, such as gene therapy using angiogenic peptides, have resulted in inconclusive results (see Ref. 12 for review). Vessel-directed progenitor cells used to enhance myocardial perfusion and substrate exchange have only resulted in temporary improvements. The mechanisms of action of cell therapy remain unsatisfactorily understood, and the magnitude of benefit demonstrated in animal models has yet to be fully translated in humans (19, 23) . Hence, novel therapeutic approaches to increase myocardial perfusion in ischemic heart disease are needed.
Thyroid hormone (TH) has well-documented effects of improving blood flow in the heart and other tissues, among other beneficial effects on cardiac contractility. However, its therapeutic use in myocardial infarction has been limited due to its associated adverse effects. TH increases heart rate, triggers arrhythmias, and can increase cardiac oxygen consumption (see Ref. 6 
for review).
Efforts have been undertaken to develop thyroid hormone analogs that selectively target specific effects (2, 4, 8, 17, 24) . However, approaches that could increase specific thyroid hormone receptors (TR) in a cell-type-specific fashion have not yet been investigated.
The central hypothesis of this work is that expression of TRs only in endothelial cells leads to increased myocardial perfusion. This approach avoids adverse cardiac effects mediated by increased TR action in cardiac myocytes. In addition, the enhanced cardiac perfusion effect occurs without undesirable systemic hemodynamic alterations and protects the ischemic myocardium against ischemic/reperfusion injury.
Therefore, we wanted to investigate whether selective expression of thyroid hormone receptor alpha-1 (TR␣ 1 ) in endothelial cells leads to beneficial effects on cardiac perfusion and protects the heart against ischemic insult. Accordingly, we generated an inducible transgenic mouse that expresses TR␣ 1 selectively in endothelial cells. Our results demonstrate that selective TR␣ 1 expression improves myocardial perfusion and confers protection against ischemia-reperfusion injury.
METHODS
The animal protocol was approved by the University of California, San Diego (UCSD), Institutional Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals as outlined by the National Institutes of Health (NIH) and the American Physiological Society.
Generation of transgenic mouse system. Endothelial cell-specific, conditional transgene expression was achieved by crossing two independent lines of transgenic mice. In one line, rat TR␣ 1 cDNA was cloned behind the tetracycline response element to generate Tet-RE TR␣ 1 transgenic mice. These Tet-RE TR␣1 transgenic mice were mated with Tie2-rtTA mice, in which expression of a codon-optimized reverse transactivator (30) (rtTA) was driven by the Tek/Tie2 promoter (28) . A graphical representation of these constructs and the resulting binary transgenic mouse model (BTG) is shown in Fig. 1A . Temporal control over endothelial TR␣ 1 transgene expression was achieved by administering doxycycline (Dox) (200 mg/l) via the drinking water for 4 wk.
Heart rate and blood pressure analysis. Following ketamine (100 mg/kg) and xylazine (10 mg/kg ip), mice were intubated and placed on a ventilator (100 -110 strokes/min, 0.4 -0.5 ml stroke volume). The right carotid artery was then exposed. A 1.4 French high-fidelity catheter-tip micromanometer (Millar Instruments, Houston, TX) was inserted retrogradely into the aorta via the right carotid artery. Aortic pressure was visualized, recorded, and archived using an AD Instruments acquisition system (Colorado Springs, CO). After both sides of the vagus nerve were cut, and following a period of pressure stabilization, baseline values were then recorded. Systolic pressure values are shown.
Langendorff preparation. Male mice (16 -24 wk old) were anesthetized with ketamine (100 mg/kg ip) and xylazine (5 mg/kg ip), and heparinized (100 U). We used an isovolumic heart preparation described previously (29) . In brief, hearts were removed from anesthetized mice and immersed in cold cardioplegic solution. After cannulation of the aorta, the hearts were perfused retrograde at 37°C with a modified Krebs-Henseleit buffer (in mmol/l: 118 NaCl, 4.7 KCl, 2.25 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.5 Na2EDTA, and 5.5 glucose). A small fluid-filled balloon was inserted into the left ventricular (LV) cavity and coupled to a pressure transducer (Millar Instruments, Houston, TX). The balloon was inflated until the diastolic pressure reached 10 mmHg. Platinum wires were placed on the surface of the right atrium and used to pace the hearts at 380 beats/min. Hearts were perfused and paced for 15 min to reach a stable cardiac function. Digitized recordings of the ventricular pressure and its first derivative were captured. Peak systolic pressure (LV pressure), end-diastolic pressure, maximum speed of contraction (ϩdP/ dt), and maximum speed of relaxation (ϪdP/dt) were analyzed from the recordings.
Determination of coronary blood flow. Coronary blood flow (CBF) was determined in vivo using nonoverlapping colors of fluorescent microspheres (Molecular Probes) (9, 25) . The left carotid artery was connected to a syringe pump to withdraw a sample for measurement of microsphere concentration in blood. A second syringe pump was loaded with fluorescent microspheres and attached to a steel cannula inserted into the left ventricle. The syringe pump taking the blood sample was activated 5 s before the second syringe pump began infusing the ventricle with microspheres. After ϳ1 min, the pump loading microspheres into the ventricle was halted, and the pump withdrawing the blood sample was stopped 10 s later. To reclaim the microspheres, the heart and the blood samples were digested in 4 M KOH at 50°C and filtered through polycarbonate filters. The filters were dissolved in 2-ethoxyethyl acetate, which released the fluorescent dye for fluorometric quantitation. CBF was determined by multiplying the fluorescence intensity of the heart sample by the rate of withdrawal of the blood sample divided by the fluorescence intensity of the blood sample, and flow in milliliters per minute was normalized for heart mass.
Coronary conductance and coronary reserve. Mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg body wt), xylazine (8 mg/kg body wt), and heparinized (100 U). Hearts were removed and retrogradely perfused via a nonrecirculating perfusion system at constant flow. Coronary flow was adjusted by varying the output of a variable-speed peristaltic pump. An initial perfusion rate of 3 ml/min for 5 min was followed by a 25-min equilibration period at a perfusion rate of 2 ml/min. All experimental measurements were initiated after this period of equilibration. The perfusion medium was Krebs-Ringer-bicarbonate solution with the following composition (in mM): 117.8 NaCl, 6 KCl, 1.6 CaCl 2, 24.2 NaHCO3, 1.2 MgSO4, 1.2 NaH2PO4, 0.027 Na2EDTA, and 5.0 glucose. This solution was equilibrated with 95% O2-5% CO2 (37°C at pH 7.4). The coronary perfusion pressure was continuously recorded via a sidearm of the perfusion cannula. Coronary vascular conductance was estimated as the ratio of perfusion flow (ml/min) to perfusion pressure (mmHg). Coronary reserve was inferred as the drop in pressure after adenosine injection. Changes in perfusion pressure were monitored, and coronary resistance was calculated.
Ischemia/reperfusion protocol. Global ischemia was initiated by stopping perfusion to the heart and submerging it into the perfusate maintained at 37°C. Pacing was ceased during the ischemic period (20 min). Following ischemia, perfusion and pacing were reinitiated and maintained for 20 min. At this point, left ventricular pressure (LVP) was evaluated.
Induction of myocardial infarction by left anterior descending coronary artery occlusion. This procedure has been described previously (14) . In brief, for studies to determine whether endothelial cell (EC) TR expression reduces myocardial infarction (MI) size, the left anterior descending (LAD) coronary artery was occluded for 1 h followed by reperfusion for 24 h. Sham-operated mice were subjected to the same surgical procedures without LAD ligation. Buprenorphine (0.1 mg/kg) was administrated subcutaneously to reduce postoperative pain. At the end of reperfusion, the LAD artery was reoccluded. 2% Evans blue dye was injected into the carotid arterial root to stain the normally perfused region blue and outline the area at risk (AAR). The LV was rapidly excised and cut into 1-mm-thick transverse sections, which were then incubated in 1% 2,3,5-triphenyltetrazolium chloride for 10 min at 37°C to differentiate the viable (red) and nonviable myocardium (pale) within the risk zone. The areas of infarction, at risk, and nonischemic LV were assessed by a blinded observer using ImageJ software (NIH). The fractions of AAR, total slice size, and MI size (MIS) to total slice size were calculated and multiplied by the weight of that slice to determine risk area and infarct weight per slice. MIS was expressed as a percentage of LV mass and as a percentage of the ischemic AAR. Hearts with infarct sizes smaller than 20% were excluded.
Isolation of coronary vascular endothelial cells. Mouse coronary ECs were isolated using a modification (16) of previously described methods (28) . Briefly, dissected heart tissues were minced and incubated with M199 containing 1 mg/ml collagenase II and 0.6 U/ml dispase II, for 1 h at 37°C. The digested material was filtered through sterile 40-m nylon mesh and washed in 2% FCS-M199. Subsequently, the cells were incubated with Dynabeads (Invitrogen), which were prepared as follows: M-450 Epoxy Dynabeads were incubated with BS-l (1 mg/ml) at 4°C for 2 d, washed with PBS containing 0.1% BSA, and incubated overnight at 4°C. The cell suspension was incubated with beads for 30 min at 4°C, and then the beads attached to ECs were captured by Dynal magnet (Invitrogen).
Analysis of capillary densities in LV myocardium. We used a method described previously (16) .
Western blot analysis. Western blots were performed as described previously (26) .
Statistical analysis. Results are presented as means Ϯ SE from at least three different experiments. Statistical significance between different groups was evaluated using one-way ANOVA with Bonferroni's multiple-comparison post hoc test. A P value Ͻ0.05 denotes the presence of a statistically significant difference.
RESULTS
General. BTG mice did not exhibit any developmental or reproductive abnormalities or any apparent phenotype before doxycycline-induced transgene expression. BTG mice showed inducible endothelial expression of the TR␣ 1 transgene at both the mRNA and protein levels (Fig. 1, B and C, respectively) . TR␣ 1 transgene-encoded mRNA was found only in the endothelial cells after induction with Dox (Fig. 1B) . Cardiac myocytes did not express the transgene. TR␣ 1 protein levels were increased twofold in coronary endothelial cells after induction compared with cells from control mice (Fig. 1C) . In contrast, TR␣ 1 protein expression did not change in isolated cardiac myocytes after BTG mice were induced with Dox (Fig. 1C) . No differences were observed in serum total T4, T3, or TSH between WT and BTG mice (Table 1) .
Hemodynamic effects of endothelial TR␣ 1 expression. Endothelial TR␣ 1 expression increased coronary blood flow, coronary conductance, and coronary reserve (77%, 60%, and 47%, respectively; Fig. 2, A-C) . We investigated whether hearts with endothelial TR␣ 1 expression show different response to T3. We challenged the mice with a daily dose of T3 for 15 days and analyzed coronary reserve. Our results showed that BTG mice responded similarly to wild-type mice ( Data are shown as means Ϯ SE; 4 animals were evaluated for each group. TSH, thyroid-stimulating hormone; BTG, binary transgenic; WT, wild type. Fig. 2 . Influence of TR␣1 expression on coronary circulation. TR␣1 expression in endothelial cells increased coronary blood flow (A) (*P ϭ 0.040; n ϭ 3), coronary conductance (B) (*P ϭ 0.0213; n ϭ 4) and coronary reserve (C) (*P ϭ 0.024; n ϭ 5) vs. WT ϩ Dox. D: effect of T3 on coronary reserve in wild-type (WT) mice and mice with endothelial TR␣1 expression (BTG) (n ϭ 5). 2D). Heart rate and body temperature were not affected by endothelial TR␣ 1 expression (Fig. 3, A and B) . Systemic blood pressure was decreased by 20% in BTG mice after TR␣ 1 expression compared with control mice (Fig. 3C) . O 2 consumption increased to a significantly lesser extent with increased rate/pressure product in BTG mice compared with WT mice (Fig. 3D) .
Mechanisms of action resulting from endothelial TR␣ 1 expression. Coronary ECs from BTG mice showed increased phosphorylated AKT levels compared with ECs from WT mice (Fig. 4A) . AKT activation was reflected in more phosphorylated endothelial nitric oxide synthase (eNOS) in BTG mice, indicating that TR␣ 1 expression stimulates eNOS activation (Fig. 4A) . These results were confirmed in vitro in cultured endothelial cells that were induced to overexpress TR␣ 1 and TR␤ 1 . Only TR␣ 1 increased eNOS phosphorylation (Fig. 4B) . Other important signaling targets in the endothelium, such as MAPK/ERK, were also affected by TR␣ 1 expression in BTG mice (Fig. 5A, 1) , where TR␣ 1 expression inhibited MAPK/ ERK phosphorylation. TR␣ 1 expression also increased protein levels of A 2A adenosine receptor, which is known to modulate coronary blood flow (27) in endothelial cells (Fig. 5A, 2) . Capillary density in the heart was not affected by endothelial TR␣ 1 expression (Fig. 5B) .
Influence of endothelial TR␣ 1 expression on ischemic insult. TR␣ 1 protein level is reduced after ischemia/reperfusion (I/R) in endothelial cells of isolated mouse hearts (Fig. 6A ) and in simulated I/R in rat aortic endothelial cells in culture (Fig. 6B) . Fig. 3 . Potential undesirable effects in BTG ϩ Dox mice. A: heart rate. B: body temperature. C: arterial blood pressure. D: cardiac O2 consumption. Endothelial expression of TR␣1 did not alter heart rate or body temperature. Blood pressure is 20% lower in BTG ϩ Dox compared with WT ϩ Dox (*P ϭ 0.038; n ϭ 5). Oxygen consumption increased to a lesser extent in BTG ϩ Dox mice compared with WT ϩ Dox mice as the rate pressure product increased (#P Ͻ 0.001; n ϭ 5). Fig. 4 . Endothelial TR␣1 expression activates the AKT/endothelial nitric oxide synthase (eNOS) signaling pathway. A: phosphorylated AKT is increased in endothelial cells from BTG ϩ Dox mice. Phosphorylated eNOS is also increased by TR␣1 expression (*P Ͻ 0.05; n ϭ 3, each sample is a pool of cells from two mouse hearts). B: influence of thyroid hormone receptor (TR) expression on eNOS. Rat aortic endothelial cells in culture were infected with adenovirus expressing TR␣1 (Adv.TR␣), TR␤1 (Adv.TR␤), or with an empty vector control adenovirus (Adv.Ctr). Western blots show that eNOS expression was not changed by TR expression. Phosphorylated eNOS (P-eNOS) was increased by 63% with TR␣1 expression. TR␤1 expression did not change P-eNOS. The P-eNOS/eNOS ratio followed the same trend. Bar graphs show summarized data of densitometry of the bands. *P Ͻ 0.05 vs. Adv.Ctr.; n ϭ 6 for each group from three separate experiments. Adv.TR␤ and Adv.Ctr were not statistically different.
Beneficial effects of endothelial TR␣ 1 expression on I/Rmediated cardiac injury were observed in contractile parameters in ex vivo experiments. Developed pressure in the left ventricle (LVP) after 20 min of no-flow ischemia in WT ϩ Dox mice decreased by 40% vs. only a 20% decline in BTG ϩ Dox mice (Fig. 6C) . Endothelial TR␣ 1 overexpression had a beneficial effect on myocardial infarct size. In BTG ϩ Dox mice, in vivo MIS is decreased by 33% compared with wild-type mice when normalized to the AAR and by 31% when normalized to the LV mass (Fig. 6D) .
DISCUSSION
Here, we describe for first time the beneficial effects of in vivo endothelium-specific expression of TR␣ 1 . Our novel transgenic model allowed us to demonstrate that increasing thyroid hormone action exclusively in the endothelium protects against ischemic insult without the adverse effects associated with systemic TH therapy.
TH vascular effects are well documented (7, 21, 22) . Moreover, endothelium-mediated T3 effects have been demon- strated in human subjects (20) . Here, we expressed TR␣ 1 in endothelial cells in an inducible fashion. Endothelial TR␣ 1 expression increased coronary flow and decreased coronary resistance. Systemic effects were also observed with a small decrease in aortic pressure that had no impact on heart rate. We could not detect an increase in heart rate in spite of lower aortic pressure, possibly because the depressing effect of the anesthetic on heart rate (11). TR␣ 1 endothelial expression did not cause other effects of TH action, such as an increase of body temperature or an increase in oxygen consumption. These effects are associated with TH action in other cell types (e.g., cardiac myocytes). Unliganded and liganded thyroid hormone receptors have been shown to exert opposite effects on the transcription of target genes in vitro; however, the occurrence of unliganded TR or its physiological role in vivo is still under discussion (1, 5). We did not observe opposite effects of TR␣ in the parameters studied in this work. We challenged BTG mice with T3 treatment and found the same magnitude of response in coronary reserve observed in wild-type mice; therefore, no silencing effect was revealed in BTG mice. One problem with T3 treatment is that T3 also stimulates TR␤. Effects mediated by this TR isoform can overlap with effects mediated by TR␣ 1 , making it difficult to interpret these results. Further work is needed to rule out unliganded effects of in vivo endothelial overexpression of TR␣ 1 .
Relaxing effects of TH in vascular myocytes have been related to AKT-eNOS activation (3). We found that endothelial TR␣ 1 expression activated AKT and increased the amount of phosphorylated eNOS. These effects may explain the observed effects of TR␣ 1 expression on coronary resistance and coronary flow, which may be mediated by an increase in NO production primarily in the endothelial cells. AKT regulates the MAPK/ERK pathway in human embryonic kidney 293 cells (31) . We have previously demonstrated that AKT activation by TR␣ 1 inhibits the MAPK/ERK pathway by phosphorylation of RAF inhibitory site at Ser-259 in cardiac myocytes (26) . Here, we found similar results where AKT activation and decreased phosphorylated ERK in endothelial cells occur after TR␣ 1 expression. Activation of the MAPK/ERK pathway plays a central role in angiogenesis (13) . Thus, the inhibitory effects of endothelial TR␣ 1 expression on the MAPK/ERK pathway and no effect on capillary density observed here confirm our previous observations that the thyroid hormone angiogenic effect is mediated exclusively by TR␤ (16) . Adenosine receptors, specifically A 2A R, have been found to be extensively expressed in vascular endothelial cells and have been widely reported to play a major role in mediating adenosine-induced endothelium-dependent vessel relaxation (27) . We found that endothelial expression of TR␣ 1 increased the level of A 2A R. Such an effect may, in part, explain the increased coronary flow and conductance observed in endothelium-specific TR ␣1 transgenic mice.
The proangiogenic effects of THs are both genomic and nongenomic (15) . We did not find changes in capillary density after TR␣ 1 expression. This is in accordance with our recent studies in mice (16) showing that T3-mediated capillary proliferation in the heart is mediated by TR␤, which primarily acts as a transcription factor.
Thyroid hormone has been used to attenuate the decreased contractile function in heart failure (10, 18). However, its clinical use has been limited due to potential arrhythmogenic and other undesirable effects. Since endothelial expression of TR␣ 1 did not affect heart rate, we investigated whether endothelial expression of TR␣ 1 was protective against ischemic insult. Our results showed that endothelial TR␣ 1 expression improved the recovery of contractility in a model of ischemia/ reperfusion in isolated mouse heart. Furthermore, in in vivo experiments using a model of myocardial infarction, endothelial expression of TR␣ 1 reduced the infarct size, demonstrating a protective effect of increasing TH action specifically in endothelial cells.
In summary, our results demonstrate that selective TR␣ 1 expression improves myocardial perfusion in the absence of adverse effects and confers protection against ischemia/reperfusion injury.
Perspectives and Significance
Myocardial infarction is provoked by an acute ischemic event. The extent of damaged myocardium could be limited by increasing coronary blood flow. Thyroid hormones have such an effect; however, undesirable effects such as an increase in heart rate prevent their use. Our results allow us to propose that increasing thyroid hormone receptor alpha-1 in endothelial cells can favor blood flow in ischemic events without undesirable effects and can have a potential therapeutic use.
